Guest content

Guest content, Insights

Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study

This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2…

Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study Read Post »

General Biotechnology, Guest content, Insights

Estimated costs of production and potential prices for the WHO Essential Medicines List

This article was originally published by Andrew M Hill, Melissa J Barber, and Dzintars Gotham in BMJ Global Health Jan 2018, 3 (1) e000571 under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. Abstract Introduction There are persi…

Estimated costs of production and potential prices for the WHO Essential Medicines List Read Post »

Guest content, Insights

Decision-making in product portfolios of pharmaceutical research and development – managing streams of innovation in highly regulated markets

This article was originally published by Antti Jekunen in Drug Des Devel Ther. 2014; 8: 2009–2016 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract Decision-making is a core function…
The post Decision-makin…

Decision-making in product portfolios of pharmaceutical research and development – managing streams of innovation in highly regulated markets Read Post »

Guest content, Insights

Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics

Originally published by  J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and Steven V. Molinski in Front. Oncol., 14 November 2017. Abstract The repositioning or…
The post Giving Drugs a Second…

Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics Read Post »

Biotechblog
Scroll to Top